2018-08-22 - Female
717391
| Adverse reaction report number | 717391 |
| Latest AER version number | 0 |
| Market authorization holder AER number | 616668 |
| Initial received date | 2018-08-22 |
| Latest received date | 2018-08-22 |
| Age | N/A |
| Gender | Female |
| Weight | N/A |
| Type of report | Study |
| Reporter type | Other Health Professional |
| Source of report | MAH |
| Report outcome | Not recovered/not resolved |
| Serious report? | Yes |
Reason for seriousness
| Death | |
| Disability | |
| Cogenital anomaly | |
| Life threateting | |
| Hospitalization | |
| Other medically important | Yes |
| Product description | Dosage form | Health product role | Route of administration | Dose | Frequency | Therapy duration | Indication(s) |
|---|---|---|---|---|---|---|---|
| OZEMPIC | SOLUTION SUBCUTANEOUS | Suspect | Unknown | 22 Day(s) | Type 2 diabetes mellitus |
| MedDRA version: v.21.1 | |
| Adverse reaction terms | Reaction duration |
|---|---|
| Abdominal pain lower | |
| Diarrhoea | |
| Haematochezia | |
| Muscle spasms | |
| Vomiting | |